The objective of this study was to detect the expression levels of VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in plasma of newly diagnosed lymphoma patients, and analyze their possible relationships with clinicopathological characteristics and prognosis. The expression levels of VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in plasma from 86 newly diagnosed lymphoma patients were detected by enzyme-linked immunosorbent assay (ELISA). As a results, the multivariate analysis showed that VEGF-C level in non-Hodgkin's lymphoma patients was low, but high in Hodgkin's lymphoma patients; VEGFR-2 level was higher in patients > 60 years, while VEGF-D level was lower in patients with IPI > 2. The univariate analysis showed that VEGF-D level was lower in patients with IPI > 2, while VEGF-D and VEGF-C levels were higher in patients without B symptoms. Relationship analysis between these factors indicated that the relation of VEGF-D expression level with VEGFR-2 and VEGFR-3 was positive. It is concluded that VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 play important roles in the pathogenesis of lymphoma, and may be used as indicators of prognosis evaluation or even guide for the antiangiogenesis treatment of lymphoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
This study aims to investigate the effect and mechanism of the herb pair Agrimoniae Herba-Coptidis Rhizoma in inhibiting angiogenesis in the colorectal cancer inflammatory microenvironment by using the method of network pharmacology and the zebrafish model. The method of network pharmacology was employed to obtain the active components, potential core targets, and signaling pathways regulated by the herb pair in inhibiting angiogenesis in the inflammatory microenvironment of colorectal cancer, on the basis of which the underlying mechanism was predicted. The zebrafish model of colorectal cancer was established, and the inflammatory microenvironment was modeled.
View Article and Find Full Text PDFCausal effect of vascular endothelial growth factor on the risk of atrial fibrillation: a two-sample Mendelian randomization study.
Front Cardiovasc Med
October 2024
Department of Cardiology, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
Article Synopsis
- * Results indicate that higher genetically predicted levels of VEGF-A and VEGF-D are linked to an increased risk of developing atrial fibrillation, with VEGF-D being particularly significant.
- * The findings suggest that elevated VEGF-D levels may causally contribute to the risk of atrial fibrillation, highlighting its potential as a target for further research and intervention.
Clinical research progress of fruquintinib in the treatment of malignant tumors.
Invest New Drugs
December 2024
Department of oncology, People's Hospital of Henan University of Chinese Medicine, Zhengzhou, 450014, Henan, China.
Article Synopsis
- * Vascular endothelial growth factor (VEGF) and its receptors (VEGFR) are key regulators of this process, and targeted therapies like fruquintinib can inhibit angiogenesis to slow down tumor growth.
- * Fruquintinib is a highly selective anti-angiogenic drug from China that targets multiple VEGFRs, showing effectiveness in various cancers and offering benefits like low toxicity and potential for combination with other treatments.
Trace-level Gabapentin can induce cardiovascular developmental toxicity through apoptosis in zebrafish larvae.
Environ Pollut
October 2024
School of Environmental Science and Engineering, Nanjing Tech University, Jiangsu, 211816, PR China; Sino-Portuguese Joint International Laboratory of Aquatic Toxicology, Nanjing Tech University, 30 South Puzhu Road, Nanjing, 211816, Jiangsu Province, PR China. Electronic address:
Gabapentin (GBP), an antiepileptic drug to treat epilepsy and neuropathic pain, has become an emerging pollutant in aquatic environments. Previous results suggested that GBP can cause a potential toxicity on the heart development of zebrafish but its cardiovascular effects are still not clear. In the current study, zebrafish embryos were exposed to GBP at environmental relevant concentrations (0, 0.
View Article and Find Full Text PDFSubconjunctival aflibercept inhibits corneal angiogenesis and VEGFR-3CD11b cells.
Graefes Arch Clin Exp Ophthalmol
December 2024
Laboratory of Ocular Regenerative Medicine and Immunology, Biomedical Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea.
Purpose: This study aimed to investigate the effects of subconjunctival injection of aflibercept, a soluble protein decoy for VEGFR-1 and VEGFR-2, on corneal angiogenesis and VEGFR-expressing CD11b cells in a mouse model of suture-induced corneal neovascularization.
Methods: Corneal neovascularization was induced in BALB/c mice by placing three sutures on the cornea. Immediately after surgery, either 200 µg aflibercept (5 µL) or an equal volume of phosphate-buffered saline (PBS) was administered into the subconjunctival space.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!